The primary patent for Ocrevus (ocrelizumab) is set to expire in 2029. This date is significant for the availability of generic versions of the multiple sclerosis treatment [1].
When does Ocrevus lose its market exclusivity?
Ocrevus, a drug used to treat relapsing forms of multiple sclerosis (MS) and primary progressive MS, has its main patent protection expiring in 2029 [1]. DrugPatentWatch.com tracks patent expiries for many pharmaceuticals, including Ocrevus [1].
What happens when Ocrevus patents expire?
Upon patent expiry, the market for Ocrevus is expected to open up to generic competition. This typically leads to a decrease in the drug's price, potentially making it more accessible to patients [1]. The development and approval of biosimilar or generic versions of Ocrevus would follow established regulatory pathways.
How does Ocrevus work?
Ocrevus is a humanized monoclonal antibody that targets B cells. It binds to the CD20 protein found on the surface of B cells and depletes them, which is believed to be the mechanism by which it reduces relapses and disease progression in MS [2].
What are the side effects of Ocrevus?
Common side effects associated with Ocrevus include infusion-related reactions, upper respiratory tract infections, and lower respiratory tract infections [3]. More serious risks can involve a rare but serious brain infection called progressive multifocal leukoencephalopathy (PML) [3].
Who manufactures Ocrevus?
Ocrevus is manufactured by Genentech, a member of the Roche Group [4].
What are the alternatives to Ocrevus for MS?
Several other disease-modifying therapies are available for multiple sclerosis, including interferons, glatiramer acetate, fingolimod, teriflunomide, dimethyl fumarate, and other monoclonal antibodies like natalizumab and alemtuzumab [5]. The choice of treatment depends on the specific type and severity of MS, as well as individual patient factors.
What is the cost of Ocrevus?
The cost of Ocrevus can vary significantly depending on insurance coverage and geographic location. However, it is generally considered a high-cost specialty medication [6]. The introduction of generic alternatives after patent expiry is anticipated to lower these costs [1].
What is the regulatory status of Ocrevus?
Ocrevus has received approval from regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for its indicated uses in MS [2, 4].
Are there any ongoing patent challenges for Ocrevus?
Information regarding specific patent challenges for Ocrevus is not provided in the given material. However, patent challenges are common for high-value drugs as competitors seek to enter the market earlier [1].
Sources
[1] DrugPatentWatch.com.
[2] https://www.gene.com/media/press-releases/14963/ocrevus-ocrelizumab-approved-by-us-food-and-drug-administration-fda-
[3] https://www.gene.com/patients/medicines/ocrevus
[4] https://www.gene.com/medicines/ocrevus
[5] https://www.nationalmssociety.org/about-multiple-sclerosis/treatment--managing-ms/medications
[6] https://www.multisclerosissociety.org.uk/about-ms/treatments-and-therapies/disease-modifying-therapies/ocrevus